Evommune (EVMN) vs MacroGenics (MGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MacroGenics is the larger company by market cap ($226.1 million vs $225.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVMN | MGNX |
|---|---|---|
| Share price | $6.22 | $3.55 |
| Market cap | $225.74M | $226.14M |
| 1-day change | -5.90% | -2.47% |
| YTD return | -63.67% | +120.50% |
| 1-year return | — | +106.40% |
| 5-year return | — | -82.02% |
| EPS (TTM) | $-3.75 | $-1.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.20 | $5.08 |
| 52-week low | $6.08 | $1.29 |
| Distance from 52-week high | -81.27% | -30.12% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +287.94% | +125.35% |
| Average volume | 675.52K | 623.51K |
| Shares outstanding | 36.29M | 63.70M |
| Employees | 48 | 293 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Healthcare · Biotechnology · 48 employees
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Healthcare · Biotechnology · 293 employees
EVMN vs MGNX FAQ
Which is bigger, Evommune or MacroGenics?
MacroGenics (MGNX) is larger, with a market capitalization of $226.14M compared with $225.74M for Evommune (EVMN).
Are Evommune and MacroGenics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.